Protein-Based Predictive Biomarkers to Personalize Neoadjuvant Therapy for Bladder Cancer-A Systematic Review of the Current Status
- PMID: 39337385
- PMCID: PMC11432686
- DOI: 10.3390/ijms25189899
Protein-Based Predictive Biomarkers to Personalize Neoadjuvant Therapy for Bladder Cancer-A Systematic Review of the Current Status
Abstract
The clinical outcome of patients with muscle-invasive bladder cancer (MIBC) is poor despite the approval of neoadjuvant chemotherapy or immunotherapy to improve overall survival after cystectomy. MIBC subtypes, immune, transcriptome, metabolomic signatures, and mutation burden have the potential to predict treatment response but none have been incorporated into clinical practice, as tumor heterogeneity and lineage plasticity influence their efficacy. Using the PRISMA statement, we conducted a systematic review of the literature, involving 135 studies published within the last five years, to identify studies reporting on the prognostic value of protein-based biomarkers for response to neoadjuvant therapy in patients with MIBC. The studies were grouped based on biomarkers related to molecular subtypes, cancer stem cell, actin-cytoskeleton, epithelial-mesenchymal transition, apoptosis, and tumor-infiltrating immune cells. These studies show the potential of protein-based biomarkers, especially in the spatial context, to reduce the influence of tumor heterogeneity on a biomarker's prognostic capability. Nevertheless, currently, there is little consensus on the methodology, reagents, and the scoring systems to allow reliable assessment of the biomarkers of interest. Furthermore, the small sample size of several studies necessitates the validation of potential prognostic biomarkers in larger multicenter cohorts before their use for individualizing neoadjuvant therapy regimens for patients with MIBC.
Keywords: bladder cancer; lineage plasticity; neoadjuvant therapy; prognostic markers; protein-based biomarkers; systematic review; tumor heterogeneity.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures

Similar articles
-
Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.Eur Urol. 2019 Jul;76(1):59-68. doi: 10.1016/j.eururo.2019.01.011. Epub 2019 Feb 1. Eur Urol. 2019. PMID: 30712971 Free PMC article.
-
Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.Eur Urol. 2019 Feb;75(2):231-239. doi: 10.1016/j.eururo.2018.09.002. Epub 2018 Oct 2. Eur Urol. 2019. PMID: 30290956 Free PMC article.
-
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.Eur Urol. 2017 Oct;72(4):544-554. doi: 10.1016/j.eururo.2017.03.030. Epub 2017 Apr 5. Eur Urol. 2017. PMID: 28390739
-
Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer.Urol Oncol. 2016 Oct;34(10):469-76. doi: 10.1016/j.urolonc.2016.05.012. Epub 2016 Jun 15. Urol Oncol. 2016. PMID: 27317490 Review.
-
Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer.Cancer Treat Rev. 2017 Mar;54:1-9. doi: 10.1016/j.ctrv.2017.01.002. Epub 2017 Jan 11. Cancer Treat Rev. 2017. PMID: 28135623 Review.
Cited by
-
Histological and immunohistochemical approaches to molecular subtyping in muscle-invasive bladder cancer.Front Oncol. 2025 Jul 15;15:1546160. doi: 10.3389/fonc.2025.1546160. eCollection 2025. Front Oncol. 2025. PMID: 40735045 Free PMC article. Review.
-
Bladder cancer biomarkers.Explor Target Antitumor Ther. 2025 Mar 25;6:1002301. doi: 10.37349/etat.2025.1002301. eCollection 2025. Explor Target Antitumor Ther. 2025. PMID: 40135048 Free PMC article. Review.
References
-
- Contieri R., Martini A., Mertens L.S., Giannatempo P., Hurle R., Witjes J.A., Ribal M.J., van Rhijn B.W., Malavaud B. The Financial Burden of Guideline-recommended Cancer Medications for Metastatic Urothelial Carcinoma. Eur. Urol. Focus. 2024 doi: 10.1016/j.euf.2023.12.002. in press . - DOI - PubMed
-
- Soares A., Bourlon M.T., Wong A., Joshi A., Jardim D., Korbenfeld E., Karak F.E., Orlandi F., Sze H., Ansari J., et al. Management of Metastatic Urothelial Carcinoma in Emerging Markets (EM): An Expert Opinion. Clin. Genitourin. Cancer. 2024;22:467–475. doi: 10.1016/j.clgc.2024.01.001. - DOI - PubMed
-
- Williams S.B., Hudgins H.K., Ray-Zack M.D., Chamie K., Smaldone M.C., Boorjian S.A., Daneshmand S., Black P.C., Kamat A.M., Goebell P.J., et al. Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer. Eur. Urol. Oncol. 2019;2:119–125. doi: 10.1016/j.euo.2018.07.006. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical